Spots Global Cancer Trial Database for haic
Every month we try and update this database with for haic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | NCT05535647 | Intrahepatic Ch... | Regorafenib and... FOLFOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | NCT05029973 | Hepatocellular ... | HAIC Sintilimab Bevacizumab Bio... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | NCT01214343 | Advanced Hepato... Carcinoma Carcinoma, Hepa... Liver Neoplasms Neoplasms | Sorafenib with ... Sorafenib | 20 Years - | Ministry of Health, Labour and Welfare, Japan | |
| Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma | NCT05617430 | Hepatocellular ... | HAIC Sintilimab Bevacizumab Bio... | 18 Years - | Wuhan Union Hospital, China | |
| TACE-HAIC vs. HAIC for Potentially Resectable HCC | NCT03591705 | Potentially Res... Hepatocellular ... | TACE-HAIC HAIC | 18 Years - 75 Years | Sun Yat-sen University | |
| Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | NCT06134193 | Carcinoma Intrahepatic Ch... Gallbladder Can... Surufatinib Angiogenesis In... Tislelizumab Antineoplastic ... Immunotherapy | HAIC Surufatinib Tislelizumab | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC | NCT05582278 | Unresectable He... | D-TACE HAIC Lenvatinib tislelizumab | 18 Years - 75 Years | Second Affiliated Hospital of Nanchang University | |
| Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma | NCT06187961 | Hepatocellular ... | HAIC Lenvatinib plus... | 18 Years - 75 Years | Tongji Hospital | |
| HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | NCT05166239 | Hepatocellular ... Portal Vein Thr... | HAIC Lenvatinib 1 PD-1 Inhibitors Lenvatinib 2 PD-1 inhibitors... | 18 Years - 80 Years | Peking University | |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | NCT05862181 | Advanced Hepato... | DEB-TACE plus H... | 18 Years - | Peking University Cancer Hospital & Institute | |
| Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma | NCT06192797 | Cholangiocarcin... | HAIC Lenvatinib plus... | 18 Years - 75 Years | Tongji Hospital | |
| The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study | NCT05121571 | Hepatocellular ... | HAIC Sorafenib | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | NCT05621499 | Hepatocellular ... | HAIC Sintilimab Lenvatinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | NCT06363825 | Advanced Hepato... | camrelizumab | 18 Years - 80 Years | Fujian Medical University | |
| Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma | NCT05166772 | Hepatocellular ... | Donafenib Sintilimab HAIC | 18 Years - 80 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC | NCT05839197 | Macrotrabecular... | HAIC Camrelizumab pl... | 18 Years - 75 Years | Tongji Hospital | |
| HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | NCT05135364 | Unresectable He... | Camrelizumab HAIC TKI | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis | NCT03009461 | HepatoCellular ... Portal Vein Thr... | HAIC Sorafenib | 18 Years - 75 Years | Peking University | |
| HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | NCT05166239 | Hepatocellular ... Portal Vein Thr... | HAIC Lenvatinib 1 PD-1 Inhibitors Lenvatinib 2 PD-1 inhibitors... | 18 Years - 80 Years | Peking University | |
| HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC | NCT03869034 | Hepatocellular ... | HAIC+PD1 HAIC | 18 Years - 70 Years | Sun Yat-sen University | |
| HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | NCT06335927 | Intrahepatic Ch... | HAIC-GEMOX+Cado... | 18 Years - 75 Years | Fudan University | |
| HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | NCT03780634 | Hepatocellular ... | HAIC PD-1 antibody Sorafenib | 18 Years - 75 Years | Sun Yat-sen University | |
| Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma | NCT05617430 | Hepatocellular ... | HAIC Sintilimab Bevacizumab Bio... | 18 Years - | Wuhan Union Hospital, China | |
| HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study | NCT05476432 | Hepatocellular ... | HAIC FOLFOX 2d FOLFOX 1d | 18 Years - 75 Years | Sun Yat-sen University | |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | NCT05713994 | Hepatocellular ... | HAIC Bevacizumab plu... Bevacizumab Bio... Lenvatinib Sorafenib Donafenib Regorafenib apatinib plus c... Anti-PD-1 monoc... | 18 Years - | Tongji Hospital | |
| Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | NCT05435313 | Colorectal Canc... | HAIC Fruquintinib Tislelizumab Raltitrexed Oxaliplatin Irinotecan | 18 Years - 75 Years | Fudan University | |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | NCT01214343 | Advanced Hepato... Carcinoma Carcinoma, Hepa... Liver Neoplasms Neoplasms | Sorafenib with ... Sorafenib | 20 Years - | Ministry of Health, Labour and Welfare, Japan | |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | NCT05713994 | Hepatocellular ... | HAIC Bevacizumab plu... Bevacizumab Bio... Lenvatinib Sorafenib Donafenib Regorafenib apatinib plus c... Anti-PD-1 monoc... | 18 Years - | Tongji Hospital | |
| HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC | NCT06364007 | Hepatocellular ... | HAIC+STRIDE+Len | 18 Years - 70 Years | Hunan Provincial People's Hospital | |
| Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | NCT05406206 | Advanced Colore... Liver Metastasi... | Fruquintinib Hepatic Arteria... | 18 Years - | Peking University Cancer Hospital & Institute | |
| HAIC Combined With Toripalimab and Donafenib for Advanced BTC | NCT05350943 | Biliary Tract A... | HAIC Gemcitabine Oxaliplatin Toripalimab Donafenib | 18 Years - 80 Years | Fudan University | |
| The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | NCT05862181 | Advanced Hepato... | DEB-TACE plus H... | 18 Years - | Peking University Cancer Hospital & Institute | |
| HAIC Combined With Toripalimab and Donafenib for Advanced BTC | NCT05350943 | Biliary Tract A... | HAIC Gemcitabine Oxaliplatin Toripalimab Donafenib | 18 Years - 80 Years | Fudan University | |
| A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma | NCT06143579 | Potentially Res... | FOLFOX-HAIC+Len... | 18 Years - | Sun Yat-sen University | |
| The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases | NCT05877001 | Colorectal Live... | Tislelizumab Regorafenib HAIC | 18 Years - | Peking University Cancer Hospital & Institute | |
| A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | NCT06363825 | Advanced Hepato... | camrelizumab | 18 Years - 80 Years | Fujian Medical University | |
| HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC | NCT05866172 | Hepatocellular ... | HAIC Zoledronic acid | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | NCT05171166 | Hepatocellular ... | HAIC TACE FOLFOX cTACE or DEB-TA... Donafenib | 18 Years - 75 Years | Peking University | |
| Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC | NCT05007587 | Hepatocellular ... | Lenvatinib mFOLFOX regimen ROX regimen | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| DEB-TACE+HAIC vs. HAIC for Large HCC | NCT05263219 | Unresectable He... | dTACE-HAIC HAIC dTACE-HAIC prot... HAIC protocol | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | NCT05511051 | Colorectal Canc... | Fruquintinib HAIC | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma | NCT05166772 | Hepatocellular ... | Donafenib Sintilimab HAIC | 18 Years - 80 Years | Tianjin Medical University Cancer Institute and Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
